title: A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer.
abstract: OBJECTIVE
  The aim of this study is to evaluate the safety and efficacy of accelerated hypofractionated radiotherapy (HypoRT) combined with sequential chemotherapy in locally advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  A total of 34 patients with stage III NSCLC were enrolled. All patients received accelerated HypoRT (initially 50Gy/20 fractions, then a fraction dose of 3Gy) using three-dimensional conformal radiation therapy (3D-CRT), omitting elective nodal irradiation (ENI), to a total dose of 65-68Gy. All patients received two cycles of induction chemotherapy; 1-2 cycles of consolidation chemotherapy were given to 31 patients. The primary outcome measure was a profile of radiation toxicity. The secondary endpoints included overall survival (OS), progression-free survival (PFS), locoregional PFS (LR-PFS) and the pattern of initial failure.
  
  
  RESULTS
  Radiation toxicity was minimal. The median and 3-year OS, PFS were 19.0 months, 32.1%; 10.0 months, 29.8%, respectively. The 1-, 2-, and 3-year LR-PFS were 69.6%, 60.9% and 60.9%, respectively. No patient experienced isolated elective nodal failure as the first site of failure.
  
  
  CONCLUSIONS
  This study suggests that accelerated HypoRT using 3D-CRT omitting ENI can be used in combination with sequential chemotherapy in locally advanced NSCLC.
authors.affiliation: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, 270 Dong An Road, Shanghai, China.
authors.forename: Zheng-Fei
authors.initials: ZF
authors.lastname: Zhu
authors.forename: Min
authors.initials: M
authors.lastname: Fan
authors.forename: Kai-Liang
authors.initials: KL
authors.lastname: Wu
authors.forename: Kuai-Le
authors.initials: KL
authors.lastname: Zhao
authors.forename: Huan-Jun
authors.initials: HJ
authors.lastname: Yang
authors.forename: Gui-Yuan
authors.initials: GY
authors.lastname: Chen
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Jiang
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Wang
authors.forename: Sen
authors.initials: S
authors.lastname: Zhao
authors.forename: Xiao-Long
authors.initials: XL
authors.lastname: Fu
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D020266:Radiotherapy, Conformal; D016896:Treatment Outcome